Get the Stockscreener App
4.39
0.68%
-0.03
After Hours:
4.51
0.12
+2.73%
Psyence Biomedical Ltd stock is traded at $4.39, with a volume of 26,345.
It is down -0.68% in the last 24 hours and up +20.58% over the past month.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$4.42
Open:
$4.29
24h Volume:
26,345
Relative Volume:
0.40
Market Cap:
$2.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.58%
1M Performance:
+20.58%
6M Performance:
-83.12%
1Y Performance:
-99.11%
1-Day Range:
$4.28
$4.505
1-Week Range:
$4.2438
$7.69
52-Week Range:
$2.9218
$699.19
Psyence Biomedical Ltd Stock (PBM) Company Profile
Compare PBM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
4.39 | 3.03M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Psyence Biomedical Ltd Stock (PBM) Latest News
Psyence Biomedical Advances Psilocybin Drug Development as of May 2025 - TipRanks
Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World
Psyence Biomedical announces reverse stock split - Investing.com
Psyence Biomedical announces reverse stock split By Investing.com - Investing.com Nigeria
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split - Newsfile
Psyence BioMed Reverse Split Cuts 4.6M Shares to 583K: What Investors Must Know Before May 5 - Stock Titan
Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks
Psyence BioMed gets Nasdaq notice for non-compliance - MSN
Psyence Group consolidates its shares - Crain's Chicago Business
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile
Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile
Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan
Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia
Psyence Biomedical reports corporate update - Investing.com
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView
Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times
Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World
Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia
Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile
Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times
Psyence Biomedical files to sell 13.81M common shares for holders - MSN
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire
Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan
Psyence Biomedical Ltd (PBM) Stock: A Value Analysis - The News Heater
Ratio Analysis: Unpacking Psyence Biomedical Ltd (PBM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Psyence Biomedical Adjusts Financials for Reverse Stock Split - TipRanks
Short Interest in Psyence Biomedical Ltd. (NASDAQ:PBMWW) Decreases By 41.0% - Defense World
Psyence Biomedical Ltd Stock (PBM) Financials Data
There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):